







an Open Access Journal by MDPI

Current Epidemiologic, Diagnostic, and Therapeutic Aspects of Cholangiocarcinoma (CCA)

Guest Editors:

Dr. Sven Loosen

Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225 Düsseldorf, Germany

Prof. Dr. Christoph Roderburg

Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany

Deadline for manuscript submissions:

closed (20 December 2024)

Message from the Guest Editors

Cholangiocarcinoma (CCA) comprises a variety heterogeneous biliary malignancies, which arises at some point of the bile duct system. CCA is associated with a globally increasing incidence, accounting for about 15% of all primary liver cancers. Due to its silent presentation of CCA in combination with the highly aggressive tumor nature and refractoriness to chemotherapy, patients are confronted with an alarmingly high mortality rate. Although the recently presented positive results on the use of checkpoint inhibitors herald a new era of palliative systemic therapy for CCA, it is currently still responsible for about 2% of all cancer-related deaths globally. New insights into epidemiological, diagnostic and therapeutic aspects, which are the focus of the current special issue, can contribute significantly to improve the care of CCA patients worldwide in order to reduce the high morbidity and mortality in the future.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us